Tag Archives: M.D.

Novartis Reports Positive Results for Atrasentan in IgA Nephropathy Study

(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release

Bayer and Cedilla Therapeutics Partner to Develop Targeted Cancer Therapies

Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, … Read the full press release

Novartis welcomes new Chief Legal Officer Karen L. Hale

(PRESS RELEASE) BASEL, 22-Mar-2021 — /EuropaWire/ — Swiss multinational pharmaceutical Novartis appoints Karen L. Hale as Chief Legal Officer. She succeeds Shannon Klinger. Karen will be based in Basel, Switzerland and will join the Executive Committee of Novartis (ECN) and … Read the full press release

Medtronic’s Hybrid Closed Loop system pivotal trial results published in the Journal of the American Medical Association

DUBLIN, 16-Sep-2016 — /EuropaWire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of its Hybrid Closed Loop system pivotal trial results in the Journal of the American Medical Association (JAMA). The data presented the safety of the system … Read the full press release

Roche: New data in rheumatoid arthritis and other severe autoimmune conditions will be presented at European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, 10-13 June 2015

40 data presentations across 7 autoimmune conditions, including new results from RoACTEMRA in early RA and systemic sclerosis (SSc) – a potentially fatal disease with limited treatment options¹ BASEL, 29-5-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today … Read the full press release

Sandoz announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN®

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online … Read the full press release

Sanofi and subsidiary Genzyme announced that FDA approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS)

Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for … Read the full press release

Sanofi: Genzyme’s Cerdelga™ capsules the only first-line oral therapy for certain adult Gaucher disease type 1 approved by FDA

Only First-Line Oral Treatment for Adult Gaucher Disease Type 1 Paris, 22-8-2014 — /EuropaWire/ — Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only … Read the full press release

Sanofi Pasteur: The New England Journal of Medicine published positive results for Fluzone® High-Dose Vaccine

Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older LYON, France, 19-8-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), … Read the full press release

Merck Serono announced the appointment of Luciano Rossetti, M.D. as Executive VP and Global Head of Research & Development

Darmstadt, Germany, 17-7-2014 — /EuropaWire/ — Merck Serono, the biopharmaceutical division of Merck, today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014. In his most recent role … Read the full press release

Roche subcutaneous formulation of RoACTEMRA received European Commission approval for moderate to severe rheumatoid arthritis treatment

First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received approval from … Read the full press release

The global leader in biosimilars Sandoz initiated Phase III clinical trial for biosimilar etanercept

Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global program underscores Sandoz’s leadership in biosimilars Holzkirchen, Germany, 1-7-2013 — /europawire.eu/ — Sandoz, the global … Read the full press release